$43.38
0[0.00%]
At close: Apr 18
$43.38
0[0.00%]
After Hours: 4:00PM EDT
Ultragenyx Pharmaceutical
(NASDAQ:RARE)Ultragenyx Pharmaceutical Stock (NASDAQ:RARE), Analyst Ratings, Price Targets, Predictions
Ultragenyx Pharmaceutical Inc has a consensus price target of $100.4, established from looking at the 63 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, Wedbush, and Cantor Fitzgerald on April 17, 2024, April 16, 2024, and April 5, 2024. With an average price target of $67.67 between Wedbush, Wedbush, and Cantor Fitzgerald, there's an implied 55.99% upside for Ultragenyx Pharmaceutical Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Cantor Fitzgerald
JP Morgan
JP Morgan
Canaccord Genuity
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ultragenyx Pharmaceutical
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 10.65% | Wedbush | Laura Chico | → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 04/16/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 10.65% | Wedbush | Laura Chico | → $48 | Reiterates | Neutral → Neutral | Get Alert |
| 04/05/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 146.66% | Cantor Fitzgerald | Kristen Kluska | → $107 | Reiterates | Overweight → Overweight | Get Alert |
| 03/18/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 112.08% | JP Morgan | Anupam Rama | $88 → $92 | Maintains | Overweight | Get Alert |
| 02/27/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 102.86% | JP Morgan | Cory Kasimov | $84 → $88 | Maintains | Overweight | Get Alert |
| 02/27/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 146.66% | Cantor Fitzgerald | Kristen Kluska | → $107 | Maintains | Overweight | Get Alert |
| 02/21/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 155.88% | Canaccord Genuity | Whitney Ijem | $110 → $111 | Maintains | Buy | Get Alert |
| 02/16/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 10.65% | Wedbush | Laura Chico | $47 → $48 | Maintains | Neutral | Get Alert |
| 02/15/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 162.79% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 01/30/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 56.75% | Baird | Joel Beatty | $57 → $68 | Maintains | Outperform | Get Alert |
| 01/19/2024 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 162.79% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 12/08/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 65.98% | Wells Fargo | Tiago Fauth | → $72 | Initiates | → Overweight | Get Alert |
| 11/03/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 93.64% | Morgan Stanley | Jeffrey Hung | $90 → $84 | Maintains | Overweight | Get Alert |
| 10/25/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 199.68% | Piper Sandler | Christopher Raymond | $135 → $130 | Maintains | Overweight | Get Alert |
| 10/10/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 107.47% | Morgan Stanley | Jeffrey Hung | $95 → $90 | Maintains | Overweight | Get Alert |
| 09/25/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 162.79% | Cantor Fitzgerald | Kristen Kluska | → $114 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 118.99% | Morgan Stanley | Jeffrey Hung | $95 → $95 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 89.03% | HC Wainwright & Co. | Ed Arce | → $82 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | RARE | Buy Now | Ultragenyx Pharmaceutical | $43.38 | 121.3% | Credit Suisse | Tiago Fauth | → $96 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Ultragenyx Pharmaceutical (RARE)?
The latest price target for Ultragenyx Pharmaceutical (NASDAQ: RARE) was reported by Wedbush on April 17, 2024. The analyst firm set a price target for $48.00 expecting RARE to rise to within 12 months (a possible 10.65% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ultragenyx Pharmaceutical (RARE)?
The latest analyst rating for Ultragenyx Pharmaceutical (NASDAQ: RARE) was provided by Wedbush, and Ultragenyx Pharmaceutical reiterated their neutral rating.
When was the last upgrade for Ultragenyx Pharmaceutical (RARE)?
The last upgrade for Ultragenyx Pharmaceutical Inc happened on June 6, 2023 when Evercore ISI Group raised their price target to $80. Evercore ISI Group previously had an in-line for Ultragenyx Pharmaceutical Inc.
When was the last downgrade for Ultragenyx Pharmaceutical (RARE)?
The last downgrade for Ultragenyx Pharmaceutical Inc happened on August 1, 2022 when Evercore ISI Group changed their price target from $95 to $60 for Ultragenyx Pharmaceutical Inc.
When is the next analyst rating going to be posted or updated for Ultragenyx Pharmaceutical (RARE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ultragenyx Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ultragenyx Pharmaceutical was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Ultragenyx Pharmaceutical (RARE) correct?
While ratings are subjective and will change, the latest Ultragenyx Pharmaceutical (RARE) rating was a reiterated with a price target of $0.00 to $48.00. The current price Ultragenyx Pharmaceutical (RARE) is trading at is $43.38, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.